Nesvacumab
- Generic Name
- Nesvacumab
- Drug Type
- Biotech
- CAS Number
- 1296818-77-3
- Unique Ingredient Identifier
- WX8293WGLC
- Background
Nesvacumab is under investigation in clinical trial NCT01997164 (Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular (Wet) Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)).
Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
Phase 1
Completed
- Conditions
- Diabetic Macular EdemaNeovascular Age-Related Macular Degeneration
- Interventions
- First Posted Date
- 2013-11-27
- Last Posted Date
- 2016-01-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT01997164
Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
Phase 1
Completed
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2012-09-20
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT01688960
Study of Nesvacumab (REGN910/ SAR307746)
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2015-06-16
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 53
- Registration Number
- NCT01271972
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath